Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Operating Margin (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Operating Margin readings, the most recent being 13.66% for Q1 2026.

  • On a quarterly basis, Operating Margin rose 403.0% to 13.66% in Q1 2026 year-over-year; TTM through Mar 2026 was 5.08%, a 836.0% increase, with the full-year FY2025 number at 3.29%, up 1407.0% from a year prior.
  • Operating Margin hit 13.66% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 17.38% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 46.82% in Q3 2022 to a low of 72.44% in Q1 2022.
  • Median Operating Margin over the past 5 years was 4.41% (2023), compared with a mean of 9.32%.
  • Biggest five-year swings in Operating Margin: surged 45461bps in 2022 and later plummeted -6312bps in 2023.
  • Kiniksa Pharmaceuticals International's Operating Margin stood at 4.08% in 2022, then skyrocketed by 102bps to 0.1% in 2023, then crashed by -16315bps to 15.75% in 2024, then dropped by -10bps to 17.38% in 2025, then skyrocketed by 179bps to 13.66% in 2026.
  • The last three reported values for Operating Margin were 13.66% (Q1 2026), 17.38% (Q4 2025), and 13.28% (Q3 2025) per Business Quant data.